Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.

Elsby, Robert; Coghlan, Hannah; Edgerton, Jacob; Hodgson, David; Outteridge, Samuel; Atkinson, Hayley

Elsby, Robert; Coghlan, Hannah; Edgerton, Jacob; Hodgson, David; Outteridge, Samuel; Atkinson, Hayley.

Afiliação

Elsby R; Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK.
Coghlan H; Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK.
Edgerton J; Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK.
Hodgson D; Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK.
Outteridge S; Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK.
Atkinson H; Department of Drug Transporter Sciences, Cyprotex Discovery Ltd (an Evotec Company), Macclesfield, Cheshire, UK.

Pharmacol Res Perspect ; 11(2): e01060, 2023 04.

Article em En | MEDLINE | ID: mdl-36811234

Assuntos

Inibidores de Proteases; Ritonavir; Rosuvastatina Cálcica; Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP; Lopinavir; Darunavir; Sulfato de Atazanavir/metabolismo; Proteínas de Neoplasias/metabolismo; Interações Medicamentosas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Proteases / Ritonavir Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google